Erschienen in:
01.12.2012 | Gynecologic Oncology
The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: Hope or Hoax?
verfasst von:
Thomas J. Herzog, MD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2012
Einloggen, um Zugang zu erhalten
Excerpt
The role of heated intraperitoneal chemotherapy (HIPEC) to treat peritoneal-based cancers has been debated for years. Meanwhile papers that advocate the advantages of this modality continue to accrue, but questions regarding efficacy, optimal indications, patient selection, and toxicity remain largely unresolved. This uncertainty for HIPEC benefit is especially acute in ovarian cancer. Is it time for clinicians to incorporate this treatment modality into the care of ovarian cancer patients? If so, then in whom should this aggressive therapy be prescribed, front-line or recurrent disease? In examining the use of this modality, one needs to consider the defining elements that constitute HIPEC therapy. …